CONTEXT: Reduced tissue nutrient exposure may aid in the progression of glucose intolerance. OBJECTIVE: The aim of the study was to examine peripheral tissue glucose disposal in relation to muscle capillarization and plasma nitric oxide bioavailability. DESIGN: Participants were carefully matched for age, adiposity, and lipid status and stratified into normal (n = 20), impaired (n = 20), and type 2 diabetic (n = 20) glucose-tolerant groups. SETTING: The study was conducted in an outpatient setting at a Clinical Research Unit. PARTICIPANTS: Older, obese men and women (n = 60; age, 65 ± 1 yr; body mass index, 32.7 ± 0.5 kg/m(2)) participated in the study. INTERVENTION: We performed a cross-sectional study. MAIN OUTCOME MEASURES: Body composition, energy metabolism, aerobic fitness (maximum oxygen consumption), insulin sensitivity (glucose clamp), vastus lateralis muscle morphology, and plasma nitric oxide were assessed. RESULTS: Although subjects were identical with respect to age, body composition, energy expenditure, and lipid status, insulin-stimulated glucose disposal and maximum oxygen consumption showed progressive decline with increasing glucose intolerance. Muscle fiber type composition and mitochondrial density were not different between groups. However, capillary density markedly declined with advancing glucose intolerance (1.86 ± 0.31, 1.70 ± 0.28, 1.42 ± 0.24 capillary/fiber; P < 0.05), a trend that was mirrored by fasting plasma nitric oxide concentrations (26.3 ± 3.6, 19.8 ± 2.3, 15.2 ± 2.1 μmol/liter; P < 0.05). Furthermore, skeletal muscle capillary density correlated with insulin sensitivity (r = 0.65; P < 0.001). CONCLUSIONS: Impaired muscle capillarization and reduced nutrient exposure to the metabolizing tissue may play a major role in the progression of insulin resistance across the glucose tolerance continuum, independent of age, adiposity, lipid status, and resting energy metabolism. These data also highlight plasma nitric oxide as a potential surrogate marker of these impairments and may be indicative of the progression toward type 2 diabetes.
CONTEXT: Reduced tissue nutrient exposure may aid in the progression of glucose intolerance. OBJECTIVE: The aim of the study was to examine peripheral tissue glucose disposal in relation to muscle capillarization and plasma nitric oxide bioavailability. DESIGN:Participants were carefully matched for age, adiposity, and lipid status and stratified into normal (n = 20), impaired (n = 20), and type 2 diabetic (n = 20) glucose-tolerant groups. SETTING: The study was conducted in an outpatient setting at a Clinical Research Unit. PARTICIPANTS: Older, obesemen and women (n = 60; age, 65 ± 1 yr; body mass index, 32.7 ± 0.5 kg/m(2)) participated in the study. INTERVENTION: We performed a cross-sectional study. MAIN OUTCOME MEASURES: Body composition, energy metabolism, aerobic fitness (maximum oxygen consumption), insulin sensitivity (glucose clamp), vastus lateralis muscle morphology, and plasma nitric oxide were assessed. RESULTS: Although subjects were identical with respect to age, body composition, energy expenditure, and lipid status, insulin-stimulated glucose disposal and maximum oxygen consumption showed progressive decline with increasing glucose intolerance. Muscle fiber type composition and mitochondrial density were not different between groups. However, capillary density markedly declined with advancing glucose intolerance (1.86 ± 0.31, 1.70 ± 0.28, 1.42 ± 0.24 capillary/fiber; P < 0.05), a trend that was mirrored by fasting plasma nitric oxide concentrations (26.3 ± 3.6, 19.8 ± 2.3, 15.2 ± 2.1 μmol/liter; P < 0.05). Furthermore, skeletal muscle capillary density correlated with insulin sensitivity (r = 0.65; P < 0.001). CONCLUSIONS: Impaired muscle capillarization and reduced nutrient exposure to the metabolizing tissue may play a major role in the progression of insulin resistance across the glucose tolerance continuum, independent of age, adiposity, lipid status, and resting energy metabolism. These data also highlight plasma nitric oxide as a potential surrogate marker of these impairments and may be indicative of the progression toward type 2 diabetes.
Authors: Martin Mogensen; Kent Sahlin; Maria Fernström; Dorte Glintborg; Birgitte F Vind; Henning Beck-Nielsen; Kurt Højlund Journal: Diabetes Date: 2007-03-09 Impact factor: 9.461
Authors: George A Brooks; Nancy F Butte; William M Rand; Jean-Pierre Flatt; Benjamin Caballero Journal: Am J Clin Nutr Date: 2004-05 Impact factor: 7.045
Authors: Edward P Weiss; Jung-Jun Park; Jennifer A McKenzie; Joon-Young Park; Onanong Kulaputana; Michael D Brown; Dana A Phares; James M Hagberg Journal: Metabolism Date: 2004-05 Impact factor: 8.694
Authors: Lucy H Clerk; Michelle A Vincent; Eugene J Barrett; Miles F Lankford; Jonathan R Lindner Journal: Am J Physiol Endocrinol Metab Date: 2007-10-02 Impact factor: 4.310
Authors: Steven J Prior; Andrew P Goldberg; Heidi K Ortmeyer; Eva R Chin; Dapeng Chen; Jacob B Blumenthal; Alice S Ryan Journal: Diabetes Date: 2015-06-11 Impact factor: 9.461
Authors: Zhuo Fu; Jing Wu; Tanseli Nesil; Ming D Li; Kevin W Aylor; Zhenqi Liu Journal: Am J Physiol Endocrinol Metab Date: 2016-11-29 Impact factor: 4.310